May 21, 2020 / 11:08 PM / 3 days ago

BRIEF-GSK Partners With Samsung Biologics To Secure Additional Manufacturing Capacity For Innovative Biopharmaceutical Portfolio

May 21 (Reuters) - GlaxoSmithKline PLC:

* GSK PARTNERS WITH SAMSUNG BIOLOGICS TO SECURE ADDITIONAL MANUFACTURING CAPACITY FOR INNOVATIVE BIOPHARMACEUTICAL PORTFOLIO

* SAMSUNG BIOLOGICS WILL PROVIDE GSK WITH ADDITIONAL CAPACITY FOR LARGE-SCALE BIOPHARMACEUTICAL PRODUCT MANUFACTURING

* AGREEMENT IS WORTH MORE THAN $231 MILLION US OVER NEXT EIGHT YEARS

* AGREEMENT TO INITIALLY COVER COMMERCIAL PRODUCTION OF BENLYSTA (BELIMUMAB), TECH TRANSFER STARTS IN 2020, FIRST COMMERCIAL SUPPLY EXPECTED IN 2022 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below